Drug intelligence / Profile preview

Wuwei Zhichuang

Development stage: Unknown
Lead developer: Fuan Pharmaceutical Group Yantai Zhi Chu Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Wuwei Zhichuang is a botanical drug candidate developed by Yantai Zhi Chu Pharmaceutical for the treatment of hemorrhoids. It is formulated as an oral capsule and has undergone Phase 1 clinical evaluation in China to assess safety and tolerability in healthy volunteers. The drug is specifically targeted at internal and mixed hemorrhoids. As a Traditional Chinese Medicine (TCM) derived product, it is designed to provide symptomatic relief, likely through anti-inflammatory and hemostatic mechanisms inherent to its herbal components.

Brand names: Wuwei Zhichuang Capsule
Other names: Wuwei Zhichuang Jiaonang

Beyond the preview

Go deeper on Wuwei Zhichuang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuwei Zhichuang.

Explore the full profile